ArticleAnnals of surgical oncology2016

Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer.

Neema Navai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.